sever
new
human
monoclon
antibodi
mab
neutral
potenti
across
differ
subtyp
recent
describ
three
mab
obtain
patient
within
cohort
institut
tropic
medicin
itm
aim
gener
immun
antibodi
equival
seen
plasma
describ
select
character
patient
plasma
mab
use
rang
neutral
assay
includ
sever
peripher
blood
mononuclear
cell
pbmc
base
assay
replic
primari
virus
well
cell
line
base
assay
pseudovirus
pv
princip
criterion
select
patient
plasma
activ
extend
incub
phase
pbmc
assay
neutral
ab
deriv
memori
b
cell
select
elisa
envelop
protein
solid
phase
mab
subsequ
test
highthroughput
hospv
assay
assess
function
neutral
present
studi
indic
strong
profil
patient
plasma
sole
due
antibodi
repres
newli
isol
mab
although
result
variou
assay
diverg
larg
indic
neutral
ab
epitop
envelop
present
plasma
synergi
ab
may
import
thu
spectrum
obtain
mab
cover
rang
crossreact
seen
plasma
care
select
patient
irrespect
neutral
assay
use
nevertheless
mab
relev
immunogen
discoveri
bind
recombin
glycoprotein
immun
respons
need
target
vivo
observ
illustr
remain
challeng
requir
success
immunogen
design
develop
despit
intens
research
effort
nearli
three
decad
minim
progress
made
develop
vaccin
retrospect
number
reason
propos
failur
enorm
genet
divers
hiv
camouflag
neutral
epitop
envelop
spike
glycan
shield
presenc
decoy
immunodomin
nonneutr
antigen
determin
nonconserv
area
surfac
low
trimer
spike
densiti
viru
membran
addit
vulner
region
may
access
short
period
shortliv
structur
includ
socal
induc
prehairpin
epitop
expos
follow
receptor
bind
subsequ
conform
chang
still
antibodi
ab
abl
success
interfer
bind
fusion
process
seen
passiv
immun
studi
macaqu
model
mab
includ
bind
mannos
residu
bind
bind
site
recogn
conform
epitop
region
bind
epitop
membran
proxim
extracellular
region
mper
last
year
howev
three
new
mab
report
african
patient
itm
cohort
taken
togeth
mab
target
three
differ
step
viral
entri
bind
thu
prevent
interact
bind
block
coreceptor
bind
final
immobil
unfold
mab
sinc
target
instead
mper
glycan
region
conceptu
advantag
avoid
potenti
auto
reactiv
importantli
mab
recent
found
confer
protect
infant
rhesu
monkey
group
ruprecht
order
gener
mab
patient
plasma
select
neutral
assay
extend
incub
time
use
activ
pbmc
panel
clinic
isol
replic
compet
strain
assay
differ
classic
short
pbmc
neutral
assay
extend
incub
phase
plasma
viru
hour
import
format
shown
shiv
challeng
trial
rhesu
macaqu
recombin
hiv
envelop
immun
induc
protect
compar
variou
neutral
assay
show
pbmc
base
assay
extend
incub
phase
abl
discrimin
protect
nonprotect
anim
vaccin
sinc
attempt
develop
vaccin
effect
rang
subtyp
subtyp
subtyp
c
circul
recombin
form
crf
respons
least
current
new
infect
worldwid
identifi
patient
whose
plasma
could
crossneutr
mainli
virus
three
subtyp
extend
incub
pbmc
assay
blood
select
patient
memori
b
cell
isol
immort
use
epstein
barr
viru
ebv
base
procedur
supernat
b
cell
clone
test
elisa
recombin
trimer
protein
sever
subtyp
solid
phase
clone
bind
activ
antigen
expand
supernat
test
use
ho
base
pv
neutral
assay
effort
ultim
result
select
new
mab
show
consider
breadth
neutral
activ
panel
primari
isol
span
tier
tier
virus
differ
subtyp
present
characterist
patient
plasma
respect
mab
multipl
neutral
assay
format
result
clearli
demonstr
patient
select
highli
depend
neutral
assay
although
crossneutr
properti
isol
ab
show
consider
variat
neutral
assay
format
assay
indic
neutral
ab
epitop
envelop
present
plasma
also
exclud
role
synergi
ab
could
play
studi
approv
institut
review
board
institut
tropic
medicin
ethic
committe
univers
hospit
antwerp
particip
understood
sign
inform
consent
elig
patient
visit
itm
clinic
antwerp
infect
least
one
year
clinic
asymptomat
year
old
neither
cell
count
viral
load
taken
consider
patient
preferenti
select
subsaharan
region
subtyp
c
andor
preval
plasma
subsequ
screen
abil
neutral
panel
four
subtyp
four
subtyp
c
six
primari
strain
extend
incub
phase
pbmc
assay
see
ab
obtain
part
collabor
aid
vaccin
discoveri
program
dr
corti
institut
research
biomedicin
bellinzona
switzerland
buffi
coat
healthi
donor
red
cross
blood
transfus
center
univers
hospit
antwerp
use
isol
pbmc
lymfoprep
axisshield
oslo
norway
centrifug
adjust
ml
cultur
medium
consist
rpmi
fetal
calf
serum
fc
lglutamin
mgml
gentamycin
lonza
vervier
belgium
mgml
polybren
sigmaaldrich
bornem
belgium
cell
stimul
mgml
phytohemagglutinin
pha
oxoid
hampshir
uk
day
day
uml
gentaur
brussel
belgium
co
incub
use
neutral
assay
follow
cell
line
obtain
nih
aid
research
refer
reagent
program
divis
aid
niaid
nih
tzmbl
dr
john
c
kapp
dr
xiaoyun
wu
tranzym
inc
ghost
isol
classifi
phylogenet
analysi
envelop
gene
viru
stock
prepar
titrat
stimul
pbmc
strain
extens
use
least
year
itm
consid
equival
neutral
resist
tier
virus
correspond
envelop
pv
construct
obtain
dna
amplif
complet
env
start
pbmc
cocultur
rtpcr
use
plasma
subsequ
clone
express
vector
includ
itm
strain
vi
vi
c
vi
c
vi
c
vi
vi
vi
ci
ca
env
express
plasmid
b
c
provid
eu
programm
eva
centr
aid
reagent
nibsc
uk
avip
contract
number
sequenc
pv
construct
phylogenet
analys
complet
confirm
ident
pv
correspond
viru
sinc
sever
paramet
influenc
observ
neutral
profil
plasma
mab
includ
comprehens
rang
differ
neutral
assay
distinct
characterist
apart
differ
target
cell
primari
cell
vs
cell
line
incub
absorpt
cultur
phase
also
investig
determin
neutral
outcom
format
differ
assay
shown
tabl
pbmc
base
assay
pbmc
neutral
assay
describ
abc
incub
time
hour
follow
mix
mab
viru
b
absorpt
time
hour
cell
expos
mabviru
mixtur
cell
wash
c
cultur
time
day
co
studi
result
obtain
format
name
extend
incub
short
incub
extend
absorpt
assay
respect
extend
incub
assay
origin
use
patient
select
describ
previous
briefli
viru
stock
dilut
five
fold
seri
cultur
medium
medium
supplement
fc
uml
establish
titer
dilut
infect
achiev
titer
constitut
poor
growth
viru
experi
discard
nineti
ml
viru
dilut
mix
ml
plasma
mg
mab
assay
test
neutral
plasma
mixtur
complement
ml
cultur
medium
give
final
dilut
plasma
test
mab
mixtur
complement
ml
flow
igg
remov
neg
plasma
use
protein
g
column
ge
healthcar
europ
gmbh
belgium
give
mgml
mab
incub
phase
ml
plasma
mab
viru
mix
first
dispens
quadrupl
flat
bottom
micropl
pbmc
ml
cultur
medium
ad
well
plate
left
co
incub
absorpt
phase
b
afterward
cell
wash
three
time
centrifug
rpm
minut
supernat
aspir
ml
fresh
cultur
medium
ad
cell
cultur
day
ml
medium
aspir
replac
ml
fresh
cultur
medium
c
day
ml
supernat
mix
ml
nonidet
pb
fluka
sigmaaldrich
puur
belgium
disrupt
virion
mixtur
analyz
presenc
hiv
antigen
control
pool
plasma
neg
donor
test
parallel
short
incub
extend
absorpt
phase
assay
time
incub
appropri
adjust
respect
neutral
activ
present
percentag
reduct
infecti
titer
viru
isol
follow
incub
patient
plasma
mab
rel
titer
follow
incub
neg
control
plasma
viru
titer
calcul
method
reed
muench
reduct
titer
consid
signific
extend
usual
one
hour
absorpt
phase
extend
short
incub
pbmc
assay
hour
format
aim
reproduc
condit
cell
line
base
assay
mab
remain
entir
absorpt
cultur
phase
pseudoviru
base
assay
neutral
capac
patient
plasma
mab
pv
tzmbl
ho
cell
relat
cell
determin
describ
luciferas
report
gene
activ
quantifi
h
infect
upon
cell
lysi
addit
firefli
luciferas
substrat
perkinelm
describ
emit
rel
light
unit
rlu
quantifi
berthold
luminomet
alabama
us
infect
tzmbl
cell
quantifi
use
steadylit
infect
ghost
cell
quantifi
use
britelit
substrat
perkinelm
preliminari
experi
tzmbl
ghost
cell
seed
well
flat
bottom
plate
infect
rang
viral
dose
total
volum
ml
establish
dose
result
signal
rlu
presenc
mgml
diethylaminoethyldextran
deaedextran
sigma
belgium
enhanc
viru
infect
tzmbl
cell
deaedextran
use
ghost
cell
actual
neutral
experi
mab
plasma
preincub
pv
h
mab
concentr
plasma
dilut
produc
reduct
luciferas
report
gene
product
determin
linear
regress
analysi
microsoft
offic
excel
describ
http
wwwhivlanlgovcontentnabreferencestrain
mab
inhibitori
concentr
determin
via
linear
interpol
method
use
mean
duplic
triplic
cultur
assay
readout
dilut
join
straight
line
plot
log
concentr
mab
posit
line
cross
assay
readout
taken
estim
ic
valu
outsid
rang
concentr
test
record
either
greater
highest
concentr
use
less
lowest
concentr
appropri
plasma
ab
calcul
dilut
seri
start
plasma
start
mg
ab
depend
ab
use
viru
titer
calcul
within
individu
experi
use
method
reed
muench
viru
dilut
seri
dose
rang
infect
cultur
infect
none
well
give
background
elisa
consid
infect
infecti
viru
titer
calcul
follow
viru
incub
mabplasma
reduct
titer
calcul
percentag
viru
titer
follow
exposur
either
igg
plasma
pool
neg
donor
purifi
igg
pool
use
control
mab
correl
calcul
use
spearman
rank
correl
test
use
prism
version
differ
correl
set
data
consid
signific
p
infect
individu
regularli
attend
clinic
itm
patient
identifi
whose
origin
subsaharan
region
africa
subtyp
subtyp
c
andor
isol
preval
plasma
evalu
therapi
least
month
therapyfre
abil
neutral
primari
strain
c
andor
subtyp
extend
incub
phase
pbmc
neutral
assay
patient
crossneutr
plasma
ie
plasma
neutral
least
strain
belong
one
subtyp
plu
least
strain
second
next
classifi
best
respond
plasma
accord
hiv
subtyp
preferenti
neutral
eg
least
three
four
c
strain
five
six
strain
gave
greater
neutral
tabl
neutral
profil
shown
patient
whose
memori
b
cell
interrog
accord
criteria
four
patient
plasma
preferenti
neutral
subtyp
strain
hgl
hgd
hqand
hgn
plasma
two
specif
subtyp
c
hvda
hk
plasma
find
patient
preferenti
recogn
strain
three
test
patient
neutral
subtyp
c
hmb
hjand
hgr
plasma
one
c
subtyp
specif
hmq
plasma
final
five
patient
display
broad
crossneutr
activ
three
subtyp
hu
hphm
hgm
hyand
hmv
plasma
remain
five
interrog
patient
display
subtyp
specif
behavior
hl
hz
hgp
hrand
hma
plasma
obviou
associ
subtyp
infect
patient
neutral
plasma
patient
newli
isol
mab
obtain
underlin
first
column
remark
plasma
patient
show
rather
subtyp
specif
neutral
profil
sinc
plasma
patient
hj
patient
neutral
mainli
c
strain
plasma
patient
hgn
patient
mainli
strain
plasma
patient
hk
patient
mainli
c
strain
tabl
clinic
histori
patient
summar
patient
specif
mab
obtain
year
old
congoles
woman
visit
clinic
sinc
receiv
treatment
intermitt
consequ
vari
count
viral
load
neutral
profil
obtain
use
plasma
sampl
taken
stop
antiretrovir
therapi
month
back
therapi
time
memori
b
cell
interrog
month
patient
receiv
antiretrovir
treatment
studi
patient
crown
specif
mab
obtain
year
old
woman
republ
guinea
regularli
attend
clinic
sinc
alway
maintain
low
viral
load
high
count
far
without
treatment
viral
load
vari
undetect
rna
copiesml
count
fluctuat
cellsml
patient
whose
mab
specif
region
year
old
ghanaian
woman
soon
arriv
belgium
test
posit
hiv
viral
load
rna
copiesml
tabl
view
known
neutral
resist
isol
consid
repres
tier
like
strain
experi
repres
tabl
addit
panel
four
subtyp
b
four
subtyp
four
strain
provid
us
overview
neutral
potenti
three
select
patient
plasma
across
six
subtyp
total
panel
tier
like
strain
observ
patient
plasma
broad
neutral
spectrum
virus
neutral
includ
c
strain
subtyp
b
strain
strain
plasma
narrow
rang
neutral
virus
includ
b
strain
strain
strain
c
strain
none
strain
plasma
neutral
virus
includ
c
strain
strain
strain
b
strain
influenc
neutral
assay
plasma
neutral
profil
three
patient
new
antibodi
isol
order
illustr
influenc
differ
assay
neutral
spectra
select
plasma
compar
result
assay
shown
tabl
except
hospv
assay
viru
panel
use
comparison
consist
nine
strain
primari
select
panel
pv
also
avail
three
strain
standard
neutnet
panel
ad
tier
b
tier
c
tier
person
commun
result
shown
tabl
compar
neutral
breadth
three
patient
plasma
three
variant
pbmc
assay
indic
hj
hk
plasma
neutral
much
fewer
virus
hgn
plasma
even
lose
signific
neutral
capac
classic
short
assay
impli
none
would
select
use
result
assay
prolong
absorpt
phase
hour
close
resembl
cell
line
base
assay
see
tabl
rescu
neutral
hgn
plasma
correl
found
result
obtain
differ
pbmc
assay
use
spearman
rank
correl
test
correl
result
extend
incub
pbmc
assay
tzmbl
assay
use
replic
compet
primari
virus
plasma
r
p
plasma
sampl
stronger
correl
three
plasma
found
plasma
pbmc
assay
tzmblpv
assay
correl
statist
signific
strongest
correl
observ
two
pv
assay
tzmblpv
ghostpv
correl
three
plasma
signific
evalu
plasma
vs
antibodi
extend
incub
pbmc
assay
neutral
profil
plasma
compar
respect
mab
extend
incub
pbmc
assay
tabl
mab
clearli
neutral
much
restrict
rang
isol
plasma
plasma
mab
neutral
subtyp
c
isol
subtyp
ci
two
three
isol
vi
plasma
mab
well
plasma
mab
neutral
b
c
mab
also
neutral
vi
b
tabl
neutral
profil
patient
plasma
differ
neutral
assay
addit
number
qualit
discrep
observ
growth
virus
strongli
inhibit
mab
enhanc
plasma
eg
subtyp
plasma
versu
mab
viceversa
eg
strain
plasma
versu
mab
type
inconsist
also
observ
group
nussenzweig
compar
new
mab
result
origin
plasma
neutralizationsensit
isol
mn
b
bal
b
ci
ad
panel
tabl
howev
limit
increas
rang
mab
reach
neutral
ci
mab
almost
neutral
bal
b
mab
activ
extra
isol
plasma
demonstr
broadest
rang
neutral
assay
also
show
activ
pbmc
celllin
assay
sinc
possibl
mab
could
share
activ
extend
evalu
assay
differ
format
tabl
rang
isol
neutral
plasma
mab
greatest
extend
incub
pbmc
assay
three
mabisol
combin
show
signific
neutral
activ
extend
absorpt
pbmc
assay
mab
neutral
three
vi
vi
six
isol
neutral
plasma
pbmc
assay
tabl
mab
neutral
vi
correspond
plasma
produc
signific
neutral
isol
assay
mab
neutral
vi
absorpt
cultur
phase
assay
extend
setup
still
neutral
vi
neutral
vi
neutral
vi
regard
cell
line
base
assay
good
concord
mab
plasma
ghostpv
assay
four
combin
also
neutral
target
cell
tzmbl
howev
infecti
viru
use
combin
enhanc
mab
neutral
vi
three
celllin
assay
correspond
plasma
fail
assay
see
tabl
remark
howev
neutral
plasma
pbmc
assay
select
vi
neutral
hj
plasma
pbmc
assay
mab
neutral
vi
ghostpv
assay
tzmblpv
assay
neutral
infecti
viru
consist
statist
signific
correl
level
neutral
reach
pbmc
assay
other
except
isol
actual
neutral
neutral
level
low
order
link
present
previou
studi
plasma
test
tzmbl
assay
subpanel
pv
includ
supplementari
tabl
refer
comparison
present
tabl
anomali
mab
neutral
isol
neutral
correspond
plasma
vice
versa
similarli
mab
show
reduc
rang
neutral
rel
correspond
plasma
plasma
patient
effect
three
tier
strain
also
five
tier
strain
contrast
correspond
mab
abl
neutral
tier
strain
although
effect
six
tier
strain
alway
isol
neutral
plasma
plasma
patient
abl
neutral
tier
strain
well
four
tier
strain
mab
also
abl
neutral
tier
strain
three
tier
strain
howev
alway
strain
neutral
plasma
plasma
hk
patient
abl
potent
neutral
three
tier
strain
none
tier
isol
mab
effect
one
three
tier
strain
one
tier
isol
proport
isol
neutral
individu
plasma
also
markedli
depend
panel
hiv
isol
use
patient
plasma
initi
select
pbmc
assay
itm
panel
primari
infecti
isol
tabl
smaller
modifi
panel
pv
use
antwerp
tabl
present
studi
base
extens
program
employ
natur
occur
broadli
neutral
ab
hivinfect
patient
templat
immunogen
design
c
primari
virus
memori
b
cell
interrog
patient
mani
mab
gener
three
show
interest
novel
broad
neutral
capac
sinc
plasma
ensu
mab
select
differ
neutral
assay
want
explor
understand
behaviour
except
plasma
mab
variou
neutral
assay
base
pbmc
cell
line
use
primari
infecti
virus
nonrepl
pv
first
observ
three
patient
neutral
mab
gener
show
intermedi
breadth
neutral
preferenti
neutral
subtyp
hgn
patient
c
hj
patient
c
hk
patient
correspond
subtyp
infect
anoth
remark
observ
show
low
viral
load
without
treatment
time
sampl
patient
hgn
profil
viraem
control
wherea
hj
chronic
progressor
patient
hk
probabl
still
earli
phase
last
two
year
sever
group
report
discoveri
new
promis
ab
ab
obtain
consortium
amongst
obtain
mean
interrog
rather
chronic
infect
patient
present
studi
patient
infect
least
year
seem
natur
control
infect
patient
may
infect
longer
year
patient
regularli
requir
antiretrovir
therapi
control
viral
load
data
confirm
neutral
ab
develop
protect
diseas
progress
similarli
broadest
neutral
plasma
obtain
patient
urgent
requir
haart
eg
hyplasma
tabl
clinic
histori
shown
sidebysid
comparison
differ
neutral
assay
use
character
patient
plasma
newli
isol
ab
show
broadest
spectrum
strain
subtyp
neutral
pv
assay
well
extend
incub
pbmc
assay
primari
viru
contrast
classic
short
incub
phase
assay
well
extend
absorpt
phase
pbmc
assay
show
reduct
number
neutral
strain
tzmbl
assay
use
primari
viru
also
show
restrict
profil
despit
fact
extend
absorpt
phase
common
cell
line
pv
assay
result
three
patient
plasma
select
crossneutr
capac
pbmc
assay
correl
obtain
tzmblpv
assay
two
patient
unusu
two
substanti
differ
techniqu
result
compar
neutral
profil
result
pv
base
assay
correl
strongli
anoth
observ
three
isol
ab
narrow
partial
differ
neutral
spectrum
rel
correspond
plasma
extend
incub
pbmc
tzmbl
pv
assay
result
mab
pbmc
tzmbl
ghost
assay
show
good
correspond
mab
ghost
neutral
respons
broader
mab
show
littl
neutral
either
tzmbl
ghost
assay
neutral
breadth
across
subtyp
unlik
due
endotoxin
sinc
plasma
neg
convent
assay
absorpt
phase
therefor
contact
plasma
cell
longer
sever
factor
may
respons
reduct
rang
isol
neutral
mab
one
reason
could
polyclon
charact
ab
plasma
crossneutr
may
requir
interact
ab
act
sever
epitop
scenario
reproduc
rang
isol
neutral
plasma
would
possibl
averag
one
two
neutral
mab
isol
would
buttress
method
directli
determin
number
individu
neutral
antibodi
clone
patient
repertoir
also
address
issu
new
studi
also
examin
group
guan
lewi
obvious
combin
isol
mab
might
correspond
better
plasma
result
addit
synergist
effect
ab
could
unveil
unfortun
obtain
mab
patient
although
obtain
mab
patient
none
except
neutral
either
ho
tzmbl
assay
nevertheless
may
miss
ab
previous
suggest
group
guan
nussenzweig
howev
nonneutr
mab
may
still
relev
wider
context
sinc
could
effector
mechan
abdepend
cellmedi
viru
inhibit
adcvi
abdepend
cellular
cytotox
adcc
fccr
altern
explan
rel
neutral
mab
obtain
primari
screen
bind
monomer
trimer
envelop
protein
elisa
procedur
might
optim
walker
studi
shown
potent
ab
bind
elisa
even
ab
bind
low
neutral
profil
infer
specif
quaternari
protein
structur
use
primari
screen
issu
address
recent
sampl
interrog
irb
within
consortium
also
note
ab
plasma
probabl
origin
plasma
cell
bone
marrow
mab
isol
memori
b
cell
circul
two
cell
popul
may
produc
rang
ab
possibl
cultur
individu
plasma
cell
clone
heavi
light
chain
variabl
region
identifi
igg
iga
repertoir
produc
select
patient
mab
isol
extrem
assay
depend
patient
gave
three
interest
mab
would
select
altern
assay
use
influenc
target
cell
neutral
alreadi
observ
us
other
particular
three
way
interact
effect
viru
antibodi
target
cell
especi
mper
specif
ab
potent
pbmc
base
assay
sinc
data
show
hj
hk
hgn
patient
potent
pbmc
neutral
assay
extend
incub
phase
could
envis
special
patient
could
high
proport
specif
ab
plasma
past
natur
occur
cross
subtyp
neutral
ab
alreadi
use
templat
immunogen
design
case
patient
select
use
either
classic
short
pbmc
assay
format
pv
assay
result
clearli
show
differ
group
patient
select
extend
incub
pbmc
assay
format
test
patient
plasma
primari
strain
also
stringent
sinc
molecularli
clone
pv
seem
easili
neutral
henc
believ
select
procedur
primari
itm
panel
provid
us
patient
potent
respons
possibl
reason
increas
sensit
primari
vs
pseudo
virus
identifi
patient
potent
neutral
ab
could
higher
number
envelop
glycoprotein
spike
primari
virus
rel
pv
altern
factor
might
densiti
co
receptor
target
cell
impli
corti
et
al
report
potent
neutral
ho
assay
almost
potenc
tzmbl
assay
sinc
recogn
epitop
region
could
partial
explain
high
level
express
tzmbl
cell
make
difficult
ab
effect
also
pathway
employ
pv
enter
tzmbl
cell
may
relev
could
hinder
event
follow
uptak
endosom
sinc
nonrepl
pv
construct
could
assess
primari
target
cell
recent
develop
molecularli
clone
construct
renilla
replic
compet
backbon
certainli
step
forward
develop
standard
pbmc
base
neutral
assay
assess
neutral
primari
cell
remain
elus
whether
mab
would
obtain
patient
like
ab
detect
elisa
although
neutral
capac
fraction
shown
still
provid
proof
signific
number
infect
patient
respond
region
briefli
expos
even
almost
year
hiv
research
ongo
search
correl
protect
still
critic
need
determin
effect
differ
type
antibodi
effector
mechan
prevent
infect
although
mani
group
tri
identifi
neutral
assay
predict
vivo
protect
issu
still
open
debat
sever
siv
shiv
macaqu
studi
neutral
mab
correl
protect
also
multipl
counter
exampl
context
compel
demonstr
preexist
ab
protect
come
passiv
immun
studi
either
igg
mab
recent
studi
use
mab
shiv
strain
contain
earli
envelop
emphas
import
potent
neutral
ab
confer
protect
heterolog
mucos
challeng
latter
highli
signific
sinc
futur
vaccin
need
effect
rel
resist
earli
founder
strain
infect
establish
vivo
taken
togeth
observ
show
singl
neutral
mab
three
patient
reflect
major
neutral
spectrum
patient
plasma
appar
correl
mab
target
hiv
strain
belong
subtyp
viru
infect
patient
quit
evid
differ
neutral
assay
yield
differ
result
still
unclear
one
predict
suit
obtain
neutral
mab
nevertheless
strategi
use
select
plasma
extend
incub
pbmc
assay
select
mab
base
elisa
bind
neutral
capac
hospv
assay
yield
interest
new
mab
better
understand
vitro
neutral
character
patient
plasma
ab
hope
lead
effect
way
discov
new
ab
ultim
use
immunogen
design
subsequ
vaccin
develop
